Home › Funds › Vivo Capital, LLC › DBVT
Vivo Capital, LLC position in DBVT
DBV Technologies SA · Health Care
Vivo Capital, LLC reported holding 1,844,758 shares of DBVT (DBV Technologies SA) in its Q3 2026 13F filing — a position valued at US$21.7M, representing 2.46% of its reported portfolio and ranking #17 among its reported holdings. Vivo Capital, LLC has disclosed DBVT holdings in 12 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's DBVT position evolved
Vivo Capital, LLC first disclosed a stake in DBVT in Q3 2023 at 2,708,875 shares (US$3.7M). The position peaked in Q1 2026 at 2,667,569 shares, worth US$55.7M. Across 12 filings, Vivo Capital, LLC increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 1,844,758 shares valued at US$21.7M. Notable position changes include a 50% trim in Q2 2024 (shares fell 13% over the following quarter), a 98% trim in Q4 2024 (shares rose 121% over the following quarter), a 133% increase in Q4 2025 (shares rose 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.71M | $3.68M | New |
| Q4 2023 | 2.71M | $2.58M | Hold |
| Q1 2024 | 2.71M | $2.03M | Hold |
| Q2 2024 | 1.35M | $1.08M | Reduce |
| Q3 2024 | 1.35M | $948.11K | Hold |
| Q4 2024 | 32.02K | $98.94K | Reduce |
| Q2 2025 | 1.05M | $9.66M | New |
| Q3 2025 | 1.05M | $10.55M | Hold |
| Q4 2025 | 2.46M | $47.19M | Add |
| Q1 2026 | 2.67M | $55.73M | Add |
| Q2 2026 | 1.84M | $30.25M | Reduce |
| Q3 2026 | 1.84M | $21.69M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DBVT and 13F data
DBVT (DBV Technologies SA) is a Health Care company. 48 other funds we track also report a position in DBVT — the largest reported positions include MPM BioImpact LLC (US$60.1M), Siren, L.L.C. (US$27.7M), PERCEPTIVE ADVISORS LLC (US$27.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DBVT
- MPM BioImpact LLC 3.67M sh · $60.13M · Q2 2026
- Siren, L.L.C. 2.36M sh · $27.71M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.65M sh · $27.11M · Q2 2026
- Logos Global Management LP 915.00K sh · $15.01M · Q2 2026
- Patient Square Capital LP 1.11M sh · $13.00M · Q3 2026
- Octagon Capital Advisors LP 574.20K sh · $9.42M · Q2 2026
- Redmile Group, LLC 410.44K sh · $6.73M · Q2 2026
- Elmind Capital, LP 265.00K sh · $4.35M · Q2 2026
- Ishara Investments LP 184.50K sh · $3.03M · Q2 2026
- Yiheng Capital Management, L.P. 170.14K sh · $2.79M · Q2 2026
- GREAT POINT PARTNERS LLC 156.91K sh · $2.57M · Q2 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held DBVT?
Vivo Capital, LLC has disclosed DBVT holdings in 12 of the last 13 reported quarters, going back to Q3 2023.
What is Vivo Capital, LLC's current position in DBVT?
As of Q3 2026, Vivo Capital, LLC holds 1.84M shares of DBVT (DBV Technologies SA), valued at $21.69M, representing 2.46% of its reported portfolio and ranking #17.
Has Vivo Capital, LLC been buying or selling DBVT?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC held unchanged its position in DBVT. The position peaked in Q1 2026 at 2.67M shares.
Which other funds hold DBVT?
Other major institutional holders of DBVT include MPM BioImpact LLC, Siren, L.L.C., PERCEPTIVE ADVISORS LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.